Frankfurt - Delayed Quote EUR

Kenvue Inc. (J4D.F)

Compare
20.15
+0.24
+(1.21%)
At close: 3:29:01 PM GMT+1
Loading Chart for J4D.F
DELL
  • Previous Close 19.90
  • Open 19.73
  • Bid 20.17 x --
  • Ask 20.37 x --
  • Day's Range 19.72 - 20.15
  • 52 Week Range 16.08 - 23.50
  • Volume 80
  • Avg. Volume 65
  • Market Cap (intraday) 39.584B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 38.01
  • EPS (TTM) 0.53
  • Earnings Date Feb 6, 2025 - Feb 10, 2025
  • Forward Dividend & Yield 0.78 (3.93%)
  • Ex-Dividend Date Nov 13, 2024
  • 1y Target Est --

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.

www.kenvue.com

22,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: J4D.F

View More

Performance Overview: J4D.F

Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

J4D.F
0.49%
S&P 500
1.35%

1-Year Return

J4D.F
8.40%
S&P 500
22.51%

3-Year Return

J4D.F
14.78%
S&P 500
24.59%

5-Year Return

J4D.F
14.78%
S&P 500
77.94%

Compare To: J4D.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: J4D.F

View More

Valuation Measures

As of 1/9/2025
  • Market Cap

    39.22B

  • Enterprise Value

    46.76B

  • Trailing P/E

    37.33

  • Forward P/E

    16.89

  • PEG Ratio (5yr expected)

    1.90

  • Price/Sales (ttm)

    2.55

  • Price/Book (mrq)

    3.70

  • Enterprise Value/Revenue

    3.12

  • Enterprise Value/EBITDA

    18.84

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.88%

  • Return on Assets (ttm)

    6.50%

  • Return on Equity (ttm)

    9.88%

  • Revenue (ttm)

    15.46B

  • Net Income Avi to Common (ttm)

    1.06B

  • Diluted EPS (ttm)

    0.53

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.06B

  • Total Debt/Equity (mrq)

    82.93%

  • Levered Free Cash Flow (ttm)

    1.52B

Research Analysis: J4D.F

View More